BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med 2021;27:125-31. [PMID: 33332878 DOI: 10.1097/MCP.0000000000000748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Arcoraci V, Squadrito F, Rottura M, Barbieri MA, Pallio G, Irrera N, Nobili A, Natoli G, Argano C, Squadrito G, Corrao S. Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register. Front Cardiovasc Med 2022;9:876693. [DOI: 10.3389/fcvm.2022.876693] [Reference Citation Analysis]
2 Verdecchia P, Cavallini C, Coiro S, Riccini C, Angeli F. Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease. Eur Heart J Suppl 2021;23:E172-6. [PMID: 34650380 DOI: 10.1093/eurheartj/suab116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Damkjær M, Suppli Ulrik C, Godtfredsen N, Håkansson KEJ. Beta-Blockers in High-Risk Outpatients with Chronic Obstructive Pulmonary Disease are Associated with All-Cause Mortality - The STATUETTE Cohort Study. Int J Chron Obstruct Pulmon Dis 2021;16:2397-406. [PMID: 34465987 DOI: 10.2147/COPD.S315151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]